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The 2 Cohort randomised PrefHer trial examined the preferences of HER2+ primary breast 
cancer patients for intravenous (IV) or subcutaneous (SC) delivery of trastuzumab via a Single 
Injectable Device (SID) or hand-held syringe (HHS). The novel approach and design of the 
study permitted an in-depth exploration of patients’ experiences, the impact that different modes 
of delivery had on patients’ well-being and implications for future management.  
 
Methods 
The preferences, experiences and general comments of patients in the PrefHer study were 
collected via specific semi-structured interview schedules. Exploratory analyses of data were 
conducted using standard methodology. The final question invited patients to make further 
comments, which were divided into 9 thematic categories – future delivery, compliments, 
time/convenience, practical considerations, pain/discomfort, study design, side-effects, 
psychological impact, and perceived efficacy. 
 
Results 
267/467 (57%) patients made 396 additional comments, 7 were neutral, 305 positive and 86 
negative. The three top categories generating the largest number of comments were 
compliments and gratitude about staff and being part of PrefHer (75/396; 19%), the potential 
future delivery of SC trastuzumab (73/396; 18%), and practical considerations about SC 
administration (60/396;15%).  
 
Conclusions 
Eliciting patient preferences about routes of administration of drugs via comprehensive 
interviews within a randomised cross-over trial yielded rich and important information. The few 
negative comments made demonstrated a need for proper staff training in SC administration 
Patients were grateful to have been part of the trial, and would have liked to continue with SC 
delivery. The possibility of home administration in the future also seemed acceptable. 
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There has been increasing recognition that inclusion of patient reported outcome (PRO) data 
enables better opportunities for more informed decision-making. For example standardised 
quality of life (QoL) instruments offer a broader assessment of the impact that different 
treatments exert on patients’ physical, functional, emotional and social well-being compared 
with adverse event reporting by physicians [1]. Other types of PROs such as patient 
preferences using study specific interview schedules may refine and influence decision-making 
further, but few trials conducted to date have such measures as their primary outcome [2].  
Anti-cancer drugs can be given orally, parentally, intravenously (IV) and subcutaneously (SC). 
All modes of administration have clinical and practical advantages and disadvantages; several 
of these may also have considerable impact upon patients’ QoL including convenience, pain 
and discomfort. Treatment can demand frequent or lengthy hospital visits, and issues such as 
the disruption to social, occupational, or family responsibilities are frequently over-looked. Out of 
pocket expenses for travel and time off work incurred by patients and their families are rarely 
considered. If drugs or methods for administering them have similar efficacy, then patient 
preferences could be important, but such information is rarely captured in trials. Health 
economics studies employing discrete choice and time trade-off methods do determine 
hypothetical preferences, but data from these do not necessarily help individual patients and 
doctors with decision-making. Few preference studies have been conducted within oncology 
contemporaneously, in real time with patients making choices between administration methods 
that they have actually experienced. If the safety and efficacy of different administration routes 
are equivalent, then the most important factor should be patient preference to ensure optimal 
treatment adherence and ultimately improve patients’ experiences and satisfaction with 
treatment [3].  
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Trastuzumab has revolutionised the treatment of HER2+ve breast cancer improving overall 
survival [4, 5].  However, women with HER2+ve early breast cancer need hospital based 
treatment lasting months or years. Most patients require surgery, adjuvant chemotherapy 
(usually given intravenously for 4-6 months) and/or hormone therapy and radiotherapy (often 
given daily for 4-6 weeks), as well as trastuzumab. Adjuvant trastuzumab is given IV every week 
or every 3 weeks for a total of 1 year. For many patients this is a considerable burden and 
disrupts their attempts to resume a more normal life-style.  The Hannah trial [6] showed that a 
fixed dose SC formulation of trastuzumab administered using a hand-held syringe (HHS) was 
non-inferior to trastuzumab administered by IV as far as pCR and serum trough were concerned 
and no new safety signals were identified. These data formed the basis of approval by the EMA 
for the SC formulation in HER2+ve early and metastatic breast cancer. The SC formulation in 
HannaH was given via a hand-held syringe (HHS) but it can also be administered via a Single 
Injectable Device (SID). 
The international, open-label, randomised PrefHer study (NCT01401166) examined preferences 
of patients with HER2+ve primary breast cancer for either IV or SC delivery of trastuzumab. The 
prospective, cross-over design addressed many of the limitations of previous work and 
unusually had patient preference as the primary outcome [2]. The trial was conducted in 10 
European countries, in Turkey and Canada. In Cohort 1, 236 patients had their trastuzumab 
administered via a SID and in Cohort 2, 231 patients had SC delivery via a HHS. Results for 
both Cohorts 1 and 2 showed an overwhelming and strong preference for the SC route of 
administration [7, 8].  The primary reasons for those (415/467; 89%) who preferred SC were that 
it saved time and resulted in less pain and discomfort. Among the small number of patients 
(45/467; 10%) who preferred IV trastuzumab, fewer bothersome reactions including less pain, 
bruising, and irritation were the primary reasons given [7, 8]. We report here a more in depth 
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exploratory analysis of patients’ experiences with IV and SC administration of trastuzumab, and 
the implications that these may have for staff training and future management. 
Methods 
Procedure 
The study design has been reported previously [8].  Briefly after completion of (neo) adjuvant 
chemotherapy, consenting patients with HER2+ve early breast cancer were randomised to 
receive either 4 cycles of SC trastuzumab (600mgs fixed dose) via the SID (Cohort 1) followed 
by 4 cycles of standard IV or the reverse sequence and in Cohort 2, the design was identical but 
trastuzumab was given SC via a HHS. Prior to randomisation and also at the end of the cross-
over period, patients were interviewed by phone at home, at a convenient time of their own 
choosing by experienced, independent interviewers.  
Assessments 
Study-specific Patient Interview Schedules (PINTs) were developed using an iterative procedure 
with the assistance of chemotherapy nurses, oncologists, psycho-oncologists and patients. After 
careful piloting and testing with English & French patient volunteers, further modifications were 
made and interviews translated before field testing in the 10 relevant languages for the 12 
countries participating in the study (Canada, Denmark, France, Germany, Italy, Poland, Russia, 
Spain, Sweden, Switzerland, Turkey and UK).  
The first PINT interview questions explored needle phobia/anxieties, past encounters with 
subcutaneous injections (e.g. vaccinations or heparin), previous experiences with IV 
chemotherapy administration via a cannula, PICC or port-a-cath, any difficulties with these such 
as pain, bruising or infection, and finally issues concerned with the setting where treatment was 
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received including relationship with staff at the chemotherapy centre and time and cost of travel 
there. 
The primary outcome explored in the second interview, conducted after the cross-over period 
when patients had experienced both IV and SC routes of administration, was preference for 
route of administration and primary reasons contributing to these. PINT2 revisited some of the 
PINT 1 questions and also addressed new topics, one of which was the hypothetical 
preferences for place where treatment should be administered, e.g. at home, in primary care, a 
local hospital or the cancer centre. In addition, women were encouraged to elaborate on any 
other issues associated with trastuzumab administration in the trial.  
Interviewers 
All interviewers from a medical interviewing organisation underwent study specific training on 
how to conduct the PrefHer interviews. They were also given a comprehensive training manual 
with a frequently asked questions section, to help them understand the types of venous access 
devices used for IV trastuzumab administration. All had to complete interviews with simulated 
patients before being approved to conduct them with study patients. Interviewers adhered to 
comprehensive standard operating procedures and entered data on-line. Contemporaneous 
quality control was conducted to ensure completion of PINTs, and avoidance of missing data. 
Interviews for Cohort 1 using the SID ran from Oct 2011 to mid-September 2012, and those for 
Cohort 2 using HHS between April 2012 and June 2013. 
Analyses 
The analyses in this paper focus on patients’ experience of receiving trastuzumab, including 
assessment of the environment, delivery time and the further comments made by participants 
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about the different treatment administration methods (question 61 the final question of the 
PINT2).   
The free responses from the final question (Q61) were recorded verbatim by the interviewer. 
Two experienced researchers using standardized methods, initially reviewed the responses 
given to generate thematic categories for initial coding and division. Redundant categories were 
removed and/or new ones created before establishing a ‘code-book’ of 9 categories. Four raters 
(VAJ, LJF, KM, CL) then independently coded the comments into 9 thematic categories.After 
independent coding any discrepancies were reconciled as needed. The 391 responses that 
participants gave to Q61 were most often one or two words or a phrase, and therefore easy to 
categorise. As such there was very little variation (95% agreement) between the coders The few 
discrepancies were all discussed and reconciled. For the final analyses, raters thoroughly 
reviewed the comments again within the categories to determine if they were positive, neutral or 
negative,  
All coders were part of the main PrefHer study team, two of whom (LJF and VAJ) had had a 
major role in developing and testing the PrefHer semi-structured interview schedules, and in 
training the foreign language interviewers. 
Results  
Both PINTs were completed by 467 randomised patients (236 for Cohort 1 and 231 for Cohort 
2). Baseline patient demographics, tumor characteristics, and treatment history were balanced 
between study arms [8]. Most patients (373/467; 80%) had already been receiving IV 
trastuzumab.  
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Experience of receiving trastuzumab 
The majority of patients (376/467; 81%) received trastuzumab in the hospital, which for most 
(75%) was also the same department where they previously had chemotherapy.  Travelling to 
receive treatment was not a problem overall (414/467; 89%) with only 6% (27/467) having >2 
hour journey. The out-of-pocket cost of travel was fairly /very burdensome for 22% patients 
(101/467), most noticeably those in Canada, Poland, and Turkey.  
The hospital environment where patients received their trastuzumab was rated as fairly / very 
pleasant by most (445/467; 95%), and all agreed that the medical and nursing staff were fairly 
or very helpful. Patients found the SC sessions more acceptable (96%; 447/467) than their IV 
delivery of trastuzumab (80%; 375/467). IV delivery also lengthened the time patients reported 
spending at the hospital; 27% (128/467) spent over 3 hours in the clinic, compared to 12% 
(58/467) when receiving SC.  
Method of administration  
Chemotherapy and previous trastuzumab had been administered via cannula for 258/467 (55%) 
patients; other Venous Access Devices (VAD) such as in-situ PICCs or Ports 204/467(44%), 
and 5/467 (1%) had experienced both routes of administration prior to starting the study.   
Just under half 120/263 (46%) reported that the staff had difficulty very often or sometimes 
when inserting cannulas and for 115/120 (96%) of these patients their final preference was for 
SC.  Only 18/209 (9%) of women reported staff having any difficulty with other VADs but 15/18 
(83%) still went on to prefer SC administration of trastuzumab. A small proportion (23/467, 5%) 
commented that some staff had difficulty with SC administration via the SID or HHS, but the 
final preferences of these women were 17 for SC administration, 5 for IV and 1 no preference. 
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Hypothetical preferences for type and setting 
At the second interview, one section examined patients’ preferences for administration of 
trastuzumab in different settings; patients were asked “If you could choose IV or SC given at: - 
cancer centre or clinic, your local hospital, your GP or primary care physician’s office or at your 
home by trained healthcare professionals which would you prefer? 
Figure 1 shows that the majority (282/467; 60%) preferred the idea of SC trastuzumab 
administration at home if it ever became available and the preference for this choice was very 
strong for 72% (204/282) and fairly strong for 22% (62/282) of women. Several patients made 
spontaneous comments illustrating reasons for preferences. Some reiterated the time and 
convenience factors associated with subcutaneous delivery generally e.g. “With SC you gain 
time. It would be beneficial to have that at home with a specialist.” Others seemed to perceive 
not only convenience but also a potential psychological benefit e.g. “As a patient I think 
Herceptin is marvellous, this advancement takes away 6 months of hospital visits. It diminishes 
the trauma. It would be ideal for patients to be able to do it at home”, and “I believe that as 
cancer patients it's important to break away from the hospital. So if it can be done at home it's 
psychologically much better”. Only 4/467 (1%) women said they would prefer IV delivery at 
hospital.  The main reason for this was that the staff there provided security as shown in this 
quote:  “I find it hard to choose between these two options. On one hand, it would be convenient 
to have it applied at home. On the other hand, I would feel safer if I was to receive the therapy 
at the medical institution. In my opinion, if anything went wrong, I would not be able to receive 
urgent advanced medical care immediately at home. Therefore, I would prefer to receive it at 
the medical institution.” 
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Question 61 Final Question 
The final question “Are there any further comments you’d like to make about the different 
methods of giving the Herceptin treatments that you have had in the study?” prompted 396 
comments from 57% (267/467) patients; (Table 1). Twelve thematic categories were initially 
generated from these, which were later reduced down to 9 categories for the final coding and 
analysis. Comments were also classified as positive (305/396, 77%), negative (86/396, 22%) or 
neutral (7/396, 2%). The top 3 categories for Cohort 1 (SID) were to do with future delivery 
45/215, (21%), compliments about the staff and or SC administration 35/215 (16%) and 
time/convenience issues 33/215 (15%). In Cohort 2 the top 3 were compliments 40/181(22%), 
future delivery 28/181 (15%) and practical considerations 28/181(15%). 
Although the final question had aimed to elicit different responses from those made in support of 
the primary outcome (preference), many just wished to reiterate their two primary reasons for 
having chosen the SC method, namely that it was far less time consuming and convenient, less 
painful and more comfortable. 
“Really like the fact that SC is quick”  
“SC is a lot more comfortable”  
“SC is a lot more pleasant, takes less time and can be done by a nurse”  
Working women and those with young families expressed a need to get on with life after 
chemotherapy. 
“I'm very happy with SC, the other is more unpleasant. Can't lead a normal life up to 24 hours 
afterwards, Need someone to look after my 2 girls” 
Busy mum with four young children – want to get on with life” 
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The hospital environment and practical capabilities of the staff administering the drug may also 
have played a role in preferences. Table 2 shows both positive and negative comments about 
this, for example, some staff, despite a study requirement for them to have viewed a training 
DVD and/or be proficient in SC delivery, lacked confidence or expertise in administering the 
drug this way. Incompetence can be painful and have an additional impact on a patient’s 
psychological well-being. 
“The first time I had it the person who administered it hadn't been trained properly and they did it 
too quickly, so it was painful and this caused my anxiety before the remaining SC sessions. “ 
(HHS) 
Gratitude was expressed by several women for the opportunity to participate in the PrefHer trial 
and to experience SC delivery of trastuzumab. 
“The study was very pleasant. One was treated well and one had the feeling of safety and trust. 
We were well looked after” 
“Content with everything and happy to have been able to participate so that it hopefully can help 
others” 
“I'm very pleased to have taken part in the study. SC is very much better. Psychologically it's 
difficult to go on to IV Herceptin after having completed chemotherapy.” 
Discussion 
Information from PROs such as patient preferences gathered via well-conceived study specific 
interview schedules may refine and influence doctor/patient decision-making but few trials 
conducted to date have outcome measures such as these as primary outcomes. The design of 
the PrefHer trial provided an ideal opportunity to explore patients’ views in more depth than is 
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usual in clinical trials about different aspects and experiences associated with different methods 
of trastuzumab administration. 
Any extra survival time achieved through treatment needs to be balanced against the efforts and 
burdens required when otherwise efficacious drugs are administered. Time is a precious 
commodity to patients with cancer and although some find regular contact and support from 
healthcare professionals valuable, a majority would prefer to spend less time waiting around in 
the much pressured environment of a busy chemotherapy centre.  
There are significant practical advantages besides the obvious convenience for patients and 
healthcare professionals; SC is a useful alternative to patients with poor venous access, 
circumvents anxieties about extravasation with cannulation and solves the problems associated 
with in-situ VADs including blockages and infection. It also saves pharmaceutical preparation 
time. Time & Motion studies have been conducted demonstrating the favourable cost efficacy of 
SC compared with IV trastuzumab in the hospital setting [9]. The way that economic costs are 
processed by cancer centres may limit the uptake of ambulatory delivery of trastuzumab and 
self-administration in appropriate patients, but this surely will eventually to lead to an overall 
reduction in healthcare costs. The results from the ongoing SafeHer study (NCT01566721) will 
provide more data not only about safety and tolerability of SC trastuzumab given either by HHS 
or by SID, but will also show how satisfied patients are with self-administration using the SID. 
Another study, ChangHer is looking at IV versus SC trastuzumab in the metastatic breast 
cancer setting. 
The PrefHer study was global and yet, irrespective of culture, the primary outcome was the 
same, with patients expressing a strong and compelling preference for SC delivery. The main 
reasons given for these preferences were perceived convenience and time saving which were 
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perhaps all the more surprising as the PrefHer trial protocol mandated extra procedures that 
might not have been needed out with a trial setting.  
Although in PrefHer many staff involved were experienced chemotherapy nurses, the study did 
reveal the importance of good, quality training. The overwhelming preference of most patients 
for SC over IV made us examine more closely the reasons given by those who still preferred IV. 
It was clear that if the SC formulation was administered too quickly, a problem with the HHS not 
the SID, then patients could find it painful. Likewise if staff were unfamiliar with placement of the 
SID then administration could be complicated and/or patients become anxious. 
In conclusion, the need for long-term trastuzumab treatment, necessitating hospital visits every 
3 weeks for a year, is not a pleasant prospect for women with breast cancer who have 
completed their surgery, and other adjuvant therapy and just want to resume normal life. The 
development of a quick and easy method of SC trastuzumab delivery goes some way to 
minimising the disruption to everyday living, enhancing quality of life. 
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Table 1:  Responses to Question 61 “Have you any other comments?”  
Cohort 1 N= 137/236; patients made 215 comments: 172 positive; 40 negative; 3 neutral 
(57/137 made multiple comments)  
Cohort 2 N= 130/231; patients made 181 comments: 131 positive; 46 negative; 4 neutral 
(44/130 made multiple comments)  
 Cohort 1 Cohort 2 Combined 
 + ve - ve - n + ve - ve - n + ve - ve - n 
Compliments  35 0 0 35 40 0 0 40 75 0 0 75 
Future Delivery 43 2 0 45 27 0 1 28 70 2 1 73 
Practical 14 16 2 32 10 17 1 28 26 33 3 60 
Time /convenience 32 1 0 33 16 4 1 21 48 5 1 54 
Pain/discomfort 20 6 0 26 11 3 0 14 31 9 0 40 
Study 11 3 0 14 12 4 1 17 23 7 1 31 
Side effects  3 10 0 13 5 12 0 17 8 22 0 30 
Psychological 11 1 0 12 7 5 0 12 18 6 0 24 
Efficacy 3 1 1 5 3 1 0 4 6 2 1 9 
Totals 172 40 3 215 131 46 4 181 305 86 7 396 
+ ve positive comment 
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Table 2: Examples of positive, negative and neutral quotes for the 9 categories 
 SID – subcutaneous I device;    HHS – hand held syringe;  
 
Category Examples of positive comments Negative and Neutral Examples 
Compliments My preference of SC therapy is very big! I loved the SC 
therapy. 
 
I would like to praise the staff at the research chemo 
unit. They were very helpful and made treatment as 
comfortable and convenient as possible. I could take 
my children with me if I needed to. 
 
Future delivery Reason for doing the trial was so that other women 
hopefully will be able to have the device. It's brilliant 
and I'd like to do it myself at home! (SID) 
SC I like a lot, but I don't want to do it myself or through carers at home. 
Communication with doctors in the oncology practice is very important to me in 
case I have questions.(HHS) 
Practical Issues SC is less constraining than IV, there is no "patch" to 
wear, no blockages 
Could the nurses have an arm support when giving the injection? It hurts if they 
move the needle during the injection but they find it hard to hold their arm still 
for 5 minutes. (HHS) 
Time/convenience Really like the SC and the fact it is quick. (SID) 
I found SC better for me because it was just one 
injection and that was it. (HHS) 
1 Hour waiting time for warming up the medicine is a bit too much. 
 
Pain/discomfort SC treatment was very quick, painless and convenient. 
(SID) 
 
They shouldn't just have given us 4 SC but all of them. 
Much more comfortable and the staff are just super. 
(HHS) 
 
With SC I felt a bit of pain in the leg in the area around were they pricked me. 
(HHS) 
I think the nursing staff touched a muscle, it was on my thigh and it was painful 
when walking, very painful actually. Also, with SC I think it would be better to 
do it in five minutes, a bit more slowly, because when it takes 3-4 minutes it is 
painful. 





Study For me Herceptin with the SC method was an 
undreamed-of solution. With the IV method I had to 
have a port. I am extremely happy to have agreed to 
take part in this trial. It was like liberation for me. (SID) 
No further comments, apart from the fact that I am 
very pleased to have been asked to take part in this 
trial. Also, both the medical and the paramedical staff 
looked after me very well.(HHS) 
I’m very satisfied to have been part of the study and 
feel that you properly get looked at more by the 
doctors. (HHS) 
I see myself unsure. Both have advantages and disadvantages. Both are good. 
SC, one is a bit disturbed by the fact that it’s individual to a nurse so it depends 
on the nurse and this gives one a funny feeling, but it's good that it's quick. I’ve 
also heard that equipment instead of an injection exists and I find this better.  
Side effects IV, overall, I had difficulties to fall asleep whereas SC 
method spread more slowly then I felt plenty of 
energy.  
 
Tiredness is one of the things I get troubled by still and when I have it SC the 
tiredness hits me in one swoop (in an hour). When I have it IV the tiredness 
spreads over 2 to 3 days. (SID) 
Too many allergies during 1 week after each injection that I have not 
experienced with the VAD (HHS)  
Psychological I would love to continue it this way. It's very pleasant, 
less psychological burden. With IV one sits in the same 
room with patients receiving chemo this doesn't make 
one feel very good  
The first time I had it the person who administered it hadn't been trained 
properly and they did it too quickly, so it was painful and this caused my anxiety 
before the remaining SC sessions.(HHS) 
I just find SC unpleasant simply because of my fear of injections.  
Efficacy I think it works better this way (SC) 
 
I wonder if Herceptin works in the same way no matter which method of 
application is used. 
As a doctor I guess that IV method more effective than SC.  
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Figure 1: Patients’ responses to hypothetical scenario of future delivery of trastuzumab  
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